Scientists hunt for metabolic clues to boost lung cancer immunotherapy

NCT ID NCT07637474

Recruiting now Knowledge-focused Sponsor: Regina Elena Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how the body's metabolism might influence whether immunotherapy drugs work in people with non-small cell lung cancer. Researchers will collect and analyze tissue samples from 150 patients to compare those who respond to treatment with those who don't. The goal is to find biological markers that predict response and discover new ways to make immunotherapy more effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help identify which lung cancer patients will benefit from immunotherapy and point to new drug targets to overcome resistance.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly help participants. Results may not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Locations

IRCCS National Cancer institute
RECRUITING

Rome, Rome, 00144, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.